Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-07-14 00:00:00 ET · period of report 2023-07-12 · accession 0000950170-23-033003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-14 | 2023-07-12 | AMLX | Olinger Margaret | Chief Commercial Off | M - OptEx | $0.37 | +20.0K | 251.1K | +9% | +$7,400 |
| D | 2023-07-14 | 2023-07-12 | AMLX | Olinger Margaret | Chief Commercial Off | M - OptEx | $0.00 | -20.0K | 69.6K | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-12 | M | A | 20,000 | $0.37 | 251,108 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-07-12 | M | D | 20,000 | $0.00 | 69,577 | D | $0.37 · — to 2029-05-13 | 20,000 Common Stock | (F1) As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023. |